This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on

• shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold),
• controlling asthma symptoms, and
• lowering the risk of asthma symptoms worsening in subjects with asthma.

Subjects with a previous diagnosis of asthma will be pre screened within 90 days prior to enrolment. If a subject develops symptoms of human rhinovirus (HRV) infection they will visit the site for assessment. Symptomatic subjects meeting all eligibility criteria will be invited to enroll.

Inclusion Criteria:

• Male and female subjects aged 18-70 years
• Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3
• Presumptive human rhinovirus infection

Exclusion Criteria:

• Current severe asthma exacerbation
• Severe asthma, GINA steps 4 or higher
• Uncontrolled or clinically significant medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol
• Current smoker, ex-smoker of <1 year, or history of smoking >/=10 pack years.